RhumbLine Advisers’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.1M | Sell |
|
|||||
|
2025
Q2 | $1.18M | Buy |
|
|||||
|
2025
Q1 | $1.04M | Sell |
|
|||||
|
2024
Q4 | $1.33M | Buy |
|
|||||
|
2024
Q3 | $683K | Buy |
|
|||||
|
2024
Q2 | $503K | Buy |
|
|||||
|
2024
Q1 | $524K | Buy |
|
|||||
|
2023
Q4 | $935K | Buy |
|
|||||
|
2023
Q3 | $649K | Sell |
|
|||||
|
2023
Q2 | $830K | Buy |
|
|||||
|
2023
Q1 | $767K | Buy |
|
|||||
|
2022
Q4 | $799K | Buy |
|
|||||
|
2022
Q3 | $867K | Buy |
|
|||||
|
2022
Q2 | $770K | Buy |
|
|||||
|
2022
Q1 | $837K | Buy |
|
|||||
|
2021
Q4 | $1.06M | Buy |
|
|||||
|
2021
Q3 | $1.08M | Buy |
|
|||||
|
2021
Q2 | $1.33M | Buy |
|
|||||
|
2021
Q1 | $756K | Buy |
|
|||||
|
2020
Q4 | $246K | Buy |
|
|||||
|
2020
Q3 | $190K | Sell |
|
|||||
|
2020
Q2 | $249K | Buy |
|
|||||
|
2020
Q1 | $104K | Buy |
|
|||||
|
2019
Q4 | $83K | Buy |
|
|||||
|
2019
Q3 | $99K | Sell |
|
|||||
|
2019
Q2 | $107K | Buy |
|
|||||
|
2018
Q2 | – | Sell |
|
|||||
|
2018
Q1 | $93K | Hold |
|
|||||
|
2017
Q4 | $108K | Sell |
|
|||||
|
2017
Q3 | $169K | Buy |
|
|||||
|
2017
Q2 | $215K | Buy |
|
|||||
|
2017
Q1 | $202K | Buy |
|
|||||
|
2016
Q4 | $133K | Sell |
|
|||||
|
2016
Q3 | $129K | Buy |
|
|||||
|
2016
Q2 | $192K | Buy |
|